Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis
Authors:
- Nicola LombardoNLNicola Lombardo
- Giovanna Lucia PiazzettaGPGiovanna Lucia Piazzetta
- Nadia LobelloNLNadia Lobello
- Giuseppe CicalaGCGiuseppe Cicala
- Maria PatafiMPMaria Patafi
- Anna Teresa BenincasaABAnna Teresa Benincasa
- Corrado PelaiaCorrado Pelaia
- Emanuela ChiarellaEmanuela Chiarella
- Girolamo PelaiaGPGirolamo Pelaia
Open Access
- 19 December 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (1) , 3
Abstract
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease of the nasal and sinus mucosa. This inflammatory process is supported by a multitude of cytokines, including IL-4, IL-5, and IL-13 produced by Th2 cells, as well as by IgE produced by B lymphocytes in response to a stimulus. Omalizumab is an anti-IgE monoclonal antibody with well-recognized roles in allergic asthma and chronic spontaneous urticaria. The aim of this study was to evaluate the clinical efficacy of omalizumab in a cohort of 13 patients suffering from chronic rhinosinusitis with CRSwNP. The inclusion criteria considered were as follows: 18 years of age, with a diagnosis of chronic rhinosinusitis with severe nasal polyposis expressed by an NPS greater than or equal to 5 and/or a SNOT-22 greater than or equal to 50. In addition, in the enrolled patients, the classic treatment with corticosteroids had to have been suspended due to recurrence after surgery or lack of response. Our results highlighted that omalizumab treatment for 16 weeks improved the parameters analyzed: SNOT-22, NPS, NRS, and NCS. The clinical efficacy of omalizumab was further strengthened by a significant improvement in respiratory function as well as reductions in the nasal polyps’ size and in the associated symptoms.Keywords
This publication has 45 references indexed in Scilit:
- Validation of a New “Objective Pain Score” Vs. “Numeric Rating Scale” For the Evaluation of Acute Pain: A Comparative StudyAnesthesiology and Pain Medicine, 2016
- Comparable actions of omalizumab on mast cells and basophilsClinical & Experimental Allergy, 2015
- Aktueller Stand der endonasalen NasennebenhöhlenchirurgieLaryngo-Rhino-Otologie, 2015
- A retrospective, cross‐sectional study reveals that women with CRSwNP have more severe disease than menImmunity, Inflammation and Disease, 2015
- Omalizumab-A reviewIndian Journal of Dermatology, 2015
- Diagnosis and management of rhinosinusitis: a practice parameter updateAnnals of Allergy, Asthma & Immunology, 2014
- Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitisJournal of Allergy and Clinical Immunology, 2013
- An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptorsImmunobiology, 2012
- Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgEBritish Journal of Clinical Pharmacology, 2011
- The health impact of chronic sinusitis in patients seeking otolaryngologic careOtolaryngology–Head and Neck Surgery, 1995